About SANBANG
SANBANG is a company based in Changchun (China) founded in 2016. SANBANG has raised $2.99 million across 2 funding rounds from investors including Su Da Tiangong Venture Capital Management and Innovation Capital. SANBANG operates in a competitive market with competitors including Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Rameda, among others.
- Headquarter Changchun, China
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website san-bangchem.com
- Total Equity Funding$2.99M (USD)
in 2 rounds
- Latest Funding Round$2.99M (USD), Seed
Oct 2020
- Investors
Funding Insights of SANBANG
SANBANG has successfully raised a total of $2.99M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.99 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.99M
- Total Rounds 2
- Last Round Seed — $2.99M
- Investors Count 2
All 2 funding rounds of SANBANG with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $2.99M | Seed | – | Su Da Tiangong Venture Capital Management | – |
| Jul 2020 | – | Seed | – | Innovation Capital | – |
2 investors in total: 2 institutional.
Investors in SANBANG
SANBANG has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Su Da Tiangong Venture Capital Management and Innovation Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | sudatiangong.com | - | |
A boutique investment bank focused on mid-market client representation. | – | innovation-capital.com | Boca Raton, United States |
Investor details for SANBANG
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of SANBANG
3 dated milestones of SANBANG across 4 years, from founding to its latest funding, stage changes and deals.
- Founded SANBANG is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $3.0M.
Competitors of SANBANG
SANBANG operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Rameda, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| enzene.com | 2006 | Pune, India | $50M | 10 | Company specializing in development of Biosimilars | |
| hybio.com.cn | 1998 | Shenzhen, China | $15M | – | Polypeptide drugs and APIs are developed and manufactured. | |
| ambiopharm.com | 2006 | North Augusta, United States | $24M | 186 | CDMO and analytical services for peptide development are provided. | |
| ocelotbio.com | 2020 | San Diego, United States | $36M | – | Ocelot Bio is a CDMO specializing in peptide manufacturing services. | |
| ramedapharma.com | 1994 | Giza, Egypt | – | 2 | Developer and manufacturer of generic pharmaceuticals, nutraceuticals, food supplements and veterinary products | |
| micot.cn | 2007 | China | $72.16M | – | Drug R&D services for cardiovascular and metabolic diseases are provided. | |
| vivitide.com | 1983 | Gardner, United States | – | 94 | Drug development services for neoantigen peptides and antibodies are provided. | |
| polypeptide.com | 1952 | Baar, Switzerland | – | – | Proprietary, GMP-grade, and non-GMP peptides are manufactured by PolyPeptide Labs. | |
| aperiambio.com | 2019 | United States | $13M | – | Industrial and therapeutic proteins are manufactured by Aperiam Bio. | |
| maruho.co.jp | 1915 | Osaka, Japan | – | – | Conducts R&D and manufactures ethical drugs for healthcare applications. |
Detailed competitors of SANBANG
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sanbang
Complete news archive for SANBANG
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SANBANG
10 companies that operate in the same segment as SANBANG (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SANBANG
SANBANG was founded in 2016 and raised its 1st funding round 4 years after it was founded.
SANBANG is headquartered in Changchun, China. It is registered at Changchun, Jilin, China.
SANBANG is a funded company, having raised a total of $2.99M across 2 funding rounds to date.
SANBANG was founded in 2016 and is based in Changchun, China. Manufacturing operations center on photoelectric materials such as OLED, alongside pharmaceutical intermediates and bioactive products. These activities support sectors like electronics and healthcare. The companys domain, san-bangchem.com, facilitates its online operations in the chemical and materials industry.
SANBANG's top competitors include Enzene Biosciences, Hybio Pharmaceutical and PolyPeptide.
SANBANG has 2 investors. Key investors include Su Da Tiangong Venture Capital Management, and Innovation Capital.